Tenax Therapeutics Reports Q2 2025 Financial Results

Tenax Therapeutics ( (TENX) ) has released its Q2 earnings. Here is a breakdown of the information Tenax Therapeutics presented to its investors.

Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on creating novel cardiopulmonary therapies, particularly for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company is currently in Phase 3 of its clinical trials.

In its recent earnings report, Tenax Therapeutics highlighted ongoing progress in its Phase 3 LEVEL study, with patient enrollment expected to complete in the first half of 2026. The company also plans to initiate a second Phase 3 study, LEVEL-2, later this year.

Key financial metrics from the second quarter of 2025 include a cash position of $105.5 million, which is expected to fund operations through 2027. Research and development expenses rose to $6.1 million, reflecting increased clinical development activities, while general and administrative expenses increased to $5.7 million due to higher non-cash stock-based compensation. The company reported a net loss of $10.9 million for the quarter.

Looking ahead, Tenax Therapeutics is poised to advance its clinical programs with the aim of meeting regulatory requirements for approval in the U.S. and other markets. The company remains focused on its strategic initiatives and expanding its operational capabilities to support its growth trajectory.